Merck KGaA buys Serono for $13.3B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Merck KGaA |
Serono |
$13.3B buyout |
The deal appears to have been heavily influenced by Merck's decision to keep Serono's headquarters in Geneva. |
|
Altana |
Nycomed |
$5.8B sale |
Germany-based Altana is selling its pharmaceutical business to Denmark's Nycomed for €4.5 billion. |
|
Hospira |
Mayne Pharma |
$2.63B buyout |
Hospira sees the move as a big boost to its international efforts in marketing generic injectables. |
|
Millennium Pharmaceuticals |
AnorMed |
$515M buyout |
Millennium Pharmaceuticals has beat out out Genzyme's bid for Millennium Pharmaceuticals. |
|
UCB |
Schwarz Pharma |
$5.6M buyout |
The two companies will enjoy about €3.3 billion in revenue and an R&D budget of €770 million. |
|
Novartis |
Cell Therapeutics |
$285M licensing deal |
The deal is for the cancer therapy Xyotax. |
|
Elan |
Transition Therapeutics |
$200M licensing deal |
The pact covers AZD-103, which is in Phase II. |
|
Pfizer |
TransTech |
$155M licensing deal |
The deal covers the worldwide rights to compounds that target the receptor for advanced glycation end products (RAGE) and have potential use in the treatment of Alzheimer's disease. |
|
Pfizer |
Atugen/SR Pharma |
$95M licensing deal |
The deal is for an RNAi treatment for age-related macular degeneration developed with Quark Biotech. |
|
Biogen Idec |
MondoBiotech |
$37.5M licensing deal |
Biogen Idec is gaining the rights to develop a new therapy for pulmonary arterial hyperntension. |
|
Schering |
AstraZeneca |
Development pact |
Germany's Schering and the UK's AstraZeneca are joining forces to develop a new therapy for breast cancer. |